Downloads: 2305

Files in This Item:
File Description SizeFormat 
s00535-009-0182-z.pdf205.52 kBAdobe PDFView/Open
Title: Gastrointestinal follicular lymphoma: review of the literature.
Authors: Yamamoto, Shuji  kyouindb  KAKEN_id
Nakase, Hiroshi  KAKEN_id
Yamashita, Kouhei  kyouindb  KAKEN_id
Matsuura, Minoru  kyouindb  KAKEN_id
Takada, Mariko
Kawanami, Chiharu
Chiba, Tsutomu  kyouindb  KAKEN_id
Author's alias: 山本, 修司
仲瀬, 裕司
Keywords: Follicular lymphoma
Gastrointestinal tract
Multiple lymphomatous polyposis
Issue Date: Apr-2010
Publisher: Springer
Journal title: Journal of gastroenterology
Volume: 45
Issue: 4
Start page: 370
End page: 388
Abstract: Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma. Although the duodenum and terminal ileum are considered to be the most common sites of origin, the development of wireless capsule endoscopy and double-balloon enteroscopy has increased the detection of GI-FL in every part of the small intestine. Approximately 70% of patients with GI-FL are estimated to have multiple lesions throughout the entire gastrointestinal tract. FL is a low-grade lymphoma that usually develops very slowly. If the lymphoma causes no symptoms, immediate treatment may not be necessary. Standard therapy has not yet been established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a combination of these therapies, is sometimes performed based on the therapeutic regimens for nodal FL. Regimens including conventional chemotherapy with rituximab, which achieve high response rates in nodal FL, are commonly used for GI-FL. The long-term clinical outcome of GI-FL is unclear. The results of a few series on the long-term outcomes of patients with GI-FL treated with conventional therapy indicate a median relapse-free time ranging from 31 to 45 months. On the other hand, in patients with GI-FL who were followed without treatment, the median time to disease progression was 37.5 months. Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision. Ongoing research on biomarkers to guide individualized GI-FL therapy may provide invaluable information that will lead to the establishment of a standard therapeutic regimen.
Rights: The original publication is available at www.springerlink.com
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/126697
DOI(Published Version): 10.1007/s00535-009-0182-z
PubMed ID: 20084529
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.